Duopharma Biotech gets premium valuation on vaccine development


Its rating is now a buy with a new discounted cashflow-derived target price of RM4 from RM3.30, which is at a 2% yield.

PETALING JAYA: Duopharma Biotech Bhd has been upgraded to a buy from a sell by RHB Research, given the increased clarity on its chances to participate in vaccine rolloutss in the country.

The research house also noted that its human insulin contract had also been extended.

Subscribe or renew your subscriptions to win prizes worth up to RM68,000!

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Trading ideas: PetDag, Atlan, Thong Guan, Maxim, Globetronics, 7-Eleven, Petron, DRB-Hicom, Dayang, MSM, Aeon, SunCon, UEM Sunrise
Oil rises 2% as Russia-Ukraine war escalates
Wall St ends higher as Dow, S&P hit one-week tops
Radium’s net profit up to RM4.8mil in 3Q
7-Eleven’s quarterly revenue climbs
SimeProp seeks quality assets for recurring income
Lower interest costs buoy TSH nine-month showing
Zetrix a profit driver for MyEG Services
NFO segment to sustain Sports Toto’s earnings
Thong Guan spreading its wings to Europe, America

Others Also Read